Skanska signs second major lease at 121 Seaport in Boston, USA, now 100 percent leased
Skanska has signed a lease with Alexion Pharmaceuticals, Inc. for about 150,000 square feet, 14,000 square meters, at its 121 Seaport office development in Boston, USA. The lease agreement is for 13 years and occupancy will take place in June 2018, when Alexion moves its headquarters to 121 Seaport. The building is now 100 percent leased.Alexion is a global biopharmaceutical company focused on developing and delivering life-changing therapies for patients with rare diseases. Located in Boston’s Innovation District, 121 Seaport